Naltrexone implantable pellets - BioCorRx
Alternative Names: BICX 102; BICX-104Latest Information Update: 28 May 2025
At a glance
- Originator BioCorRx
- Developer BioCorRx; National Institute of Drug Abuse
- Class Anti-inflammatories; Antineoplastics; Antivirals; Cyclopropanes; Drug withdrawal therapies; Ethers; Eye disorder therapies; Irritable bowel syndrome therapies; Ketones; Morphinans; Non-opioid analgesics; Small molecules
- Mechanism of Action Opioid receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Alcoholism; Opioid-related disorders
Most Recent Events
- 28 May 2025 No recent reports of development identified for phase-I development in Alcoholism(In volunteers) in USA (SC)
- 28 May 2025 No recent reports of development identified for phase-I development in Opioid-related-disorders(In volunteers) in USA (SC, Pellet)
- 15 Aug 2024 BioCorRx received a new patent grant in the US and Israel for Naltrexone implantable pellets